GLP-1 receptor agonists are among the most actively researched compound classes in metabolic science. Three compounds dominate current research interest: Semaglutide, Tirzepatide, and Retatrutide. Here is how they compare.
Semaglutide
Semaglutide is a GLP-1 receptor agonist with a long half-life of approximately 7 days, making it suitable for once-weekly research protocols. It works by mimicking the GLP-1 hormone, which plays a key role in insulin secretion, glucagon suppression, and satiety signalling. Semaglutide acts on a single receptor target (GLP-1R).
Tirzepatide
Tirzepatide is a dual agonist, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP receptor activity appears to produce additive effects on metabolic endpoints in research settings. Tirzepatide also has a weekly half-life profile similar to Semaglutide.
Retatrutide
Retatrutide is a triple agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds a thermogenic element to the compound’s research profile, making it the most multi-mechanistic of the three. Research with Retatrutide is ongoing and it represents the frontier of GLP-1 class compounds.
Key Differences at a Glance
Semaglutide: GLP-1 agonist only. Well-established research profile. Weekly dosing.
Tirzepatide: GLP-1 + GIP dual agonist. Enhanced metabolic effects in research. Weekly dosing.
Retatrutide: GLP-1 + GIP + Glucagon triple agonist. Newest of the three. Most complex mechanism.
All three compounds are available at EhBuddy Peptides for research purposes.
All products are sold for laboratory and scientific research purposes only and are not intended for human or veterinary use.
